Analysts Expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Announce -$0.41 Earnings Per Share

Share on StockTwits

Wall Street brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.41) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($0.45) to ($0.39). Syros Pharmaceuticals posted earnings of ($0.43) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.7%. The business is expected to announce its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.79) per share for the current year, with EPS estimates ranging from ($1.99) to ($1.67). For the next year, analysts expect that the firm will report earnings of ($1.82) per share, with EPS estimates ranging from ($2.19) to ($1.59). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.08. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.42 million.

SYRS has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 9th. HC Wainwright reissued a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Piper Jaffray Companies set a $44.00 price target on shares of First Merchants and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research note on Friday, July 12th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Wedbush reissued an “outperform” rating on shares of Alphabet in a research note on Thursday, April 25th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $16.03.

In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total value of $489,510.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 14.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Northern Trust Corp boosted its holdings in Syros Pharmaceuticals by 0.7% in the fourth quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after purchasing an additional 2,179 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Syros Pharmaceuticals by 8.3% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after purchasing an additional 3,100 shares during the last quarter. Alps Advisors Inc. boosted its holdings in Syros Pharmaceuticals by 4.5% in the first quarter. Alps Advisors Inc. now owns 81,287 shares of the company’s stock worth $743,000 after purchasing an additional 3,519 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Syros Pharmaceuticals by 3.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after purchasing an additional 3,900 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new stake in Syros Pharmaceuticals in the first quarter worth approximately $48,000. Institutional investors own 56.16% of the company’s stock.

SYRS stock traded up $0.12 during trading on Wednesday, reaching $7.52. The company had a trading volume of 1,710 shares, compared to its average volume of 305,879. Syros Pharmaceuticals has a 52 week low of $5.17 and a 52 week high of $13.16. The stock has a market cap of $313.98 million, a P/E ratio of -3.94 and a beta of 1.94. The business’s 50 day moving average price is $7.18. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.19 and a current ratio of 5.19.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: How to Use a Moving Average for TradingĀ 

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pinnacle Associates Ltd. Cuts Position in Yandex NV
Pinnacle Associates Ltd. Cuts Position in Yandex NV
Shepherd Financial Partners LLC Sells 592 Shares of Procter & Gamble Co
Shepherd Financial Partners LLC Sells 592 Shares of Procter & Gamble Co
Pinnacle Associates Ltd. Purchases 689 Shares of Walt Disney Co
Pinnacle Associates Ltd. Purchases 689 Shares of Walt Disney Co
Old Republic International Co.  Shares Sold by Pinnacle Associates Ltd.
Old Republic International Co. Shares Sold by Pinnacle Associates Ltd.
Pinnacle Associates Ltd. Raises Stock Position in Rockwell Automation
Pinnacle Associates Ltd. Raises Stock Position in Rockwell Automation
Amyris Inc  Stock Position Lessened by Pinnacle Associates Ltd.
Amyris Inc Stock Position Lessened by Pinnacle Associates Ltd.


© 2006-2019 Ticker Report